Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders, according to the presenters' agreement to release them.
Login and Watch now!
IMpassion050: A phase 3 study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy in high-risk, HER2-positive early breast cancer
- Start date
- 17 Jun 2021
- End date
- 18 Jun 2021
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
Programme
Thursday, 17 June 2021
19:30-20:30 CEST
Welcome and introduction, Scientific background and context
Nadia Harbeck, LMU Klinikum der Universität München, Munich, Germany
IMpassion050: A phase 3 study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy in high-risk, HER2-positive early breast cancer
Jens Huober, Cantonal Hospital, Breast Center St. Gallen, St. Gallen, Switzerland
Critical analysis and perspectives
Evandro de Azambuja, Institute Jules Bordet, Brussels, Belgium
Discussion and Q&A (i)
Faculty and online audience
Friday, 18 June 2021
13:15-14:15 CEST (19:15 HKT / 20:15 JST / 21:15 AEST)
Webcast of 17 June presentations, Discussion and Q&A (ii)
Faculty and online audience:
Chair: Yeon Hee Park, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Jens Huober, Cantonal Hospital, Breast Center St. Gallen, St. Gallen, Switzerland
Evandro de Azambuja, Institute Jules Bordet, Brussels, Belgium
Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia
Shigehira Saji, Saitama, Fukushima Medical University, Fukushima, Japan
